...
首页> 外文期刊>World Journal of Surgery: Official Journal of the Societe Internationale de Chirurgie, Collegium Internationale Chirurgiae Digestivae, and of the International Association of Endocrine Surgeons >Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?
【24h】

Tumor protein p53-induced nuclear protein (TP53INP1) expression in medullary thyroid carcinoma: a molecular guide to the optimal extent of surgery?

机译:甲状腺髓样癌中肿瘤蛋白p53诱导的核蛋白(TP53INP1)表达:最佳手术范围的分子指南?

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Medullary thyroid cancer (MTC) is characterized by early regional lymph node metastasis, the presence of which represents a critical obstacle to cure. At present no molecular markers have been successfully integrated into the clinical care of sporadic MTC. The present study was designed to evaluate TP53INP1 expression in MTC and to assess its ability to guide the surgeon to the optimal extent of surgery performed with curative intent. METHODS: Thirty-eight patients with sporadic MTC were evaluated. TP53INP1 immunoexpression was studied on embedded paraffin material and on cytological smears. RESULTS: TP53INP1 was expressed in normal C cells, in C-cell hyperplasia, and in 57.9% of MTC. It was possible to identify two groups of MTC according to the proportion of TP53INP1 expressing tumor cells: group 1 from 0% to <50% and group 2 from 50% to 100% of positive cells. Patients with a decreased expression of TP53INP1 (group 1) had a lower rate of nodal metastasis (18.8% versus 63.4% in group 2; P = 0.009), with only minimal lymph node involvement per N1 patient (2.7% of positive lymph nodes versus 22.9%; P < 0.001) and better outcomes (100% of biochemical cure versus 55.5%; P < 0.001). Patients with distant metastases were only observed in group 2. Cytological samples exhibit similar results to their embedded counterparts. CONCLUSIONS: TP53INP1 immunoexpression appears to be a clinical predictor of lymph node metastasis in MTC. The evaluation of TP53INP1 expression may guide the extent of lymph node dissection in the clinically node-negative neck. These findings require prospective validation.
机译:背景:甲状腺髓样癌(MTC)的特征是早期区域淋巴结转移,其存在代表了治愈的关键障碍。目前,尚无分子标记已成功整合到散发性MTC的临床护理中。本研究旨在评估TP53INP1在MTC中的表达,并评估其指导医生达到根治性目的进行手术的最佳程度的能力。方法:对38例散发性MTC患者进行了评估。 TP53INP1免疫表达在石蜡包埋材料和细胞涂片上进行了研究。结果:TP53INP1在正常C细胞,C细胞增生和57.9%的MTC中表达。根据表达TP53INP1的肿瘤细胞的比例,可以确定两组MTC:第1组为阳性细胞的0%至<50%,第2组为50%至100%的阳性细胞。 TP53INP1表达降低的患者(第1组)的淋巴结转移率较低(28.8%,第2组为63.4%; P = 0.009),每位N1患者淋巴结受累最少(阳性淋巴结的2.7% 22.9%; P <0.001)和更好的结局(100%生化治疗对55.5%; P <0.001)。仅在第2组中观察到了远处转移的患者。细胞学样本显示出与嵌入式样本相似的结果。结论:TP53INP1的免疫表达似乎是MTC淋巴结转移的临床预测指标。 TP53INP1表达的评估可能指导临床淋巴结阴性颈部淋巴结清扫的程度。这些发现需要前瞻性验证。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号